Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Capital Employed (2017 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Return on Capital Employed for 11 consecutive years, with 1.18% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 57.0% to 1.18% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.18% through Dec 2025, down 57.0% year-over-year, with the annual reading at 0.61% for FY2025, 12.0% down from the prior year.
  • Return on Capital Employed hit 1.18% in Q4 2025 for Vistagen Therapeutics, down from 1.07% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.17% in Q1 2021 to a low of 3.32% in Q2 2023.
  • Historically, Return on Capital Employed has averaged 0.99% across 5 years, with a median of 0.68% in 2022.
  • Biggest five-year swings in Return on Capital Employed: skyrocketed 514bps in 2021 and later crashed -228bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.42% in 2021, then tumbled by -392bps to 2.06% in 2022, then skyrocketed by 80bps to 0.41% in 2023, then crashed by -46bps to 0.6% in 2024, then crashed by -95bps to 1.18% in 2025.
  • Business Quant data shows Return on Capital Employed for VTGN at 1.18% in Q4 2025, 1.07% in Q3 2025, and 0.91% in Q2 2025.